GT200300193A - Formulaciones que comprenden un compuesto de indolinona - Google Patents

Formulaciones que comprenden un compuesto de indolinona

Info

Publication number
GT200300193A
GT200300193A GT200300193A GT200300193A GT200300193A GT 200300193 A GT200300193 A GT 200300193A GT 200300193 A GT200300193 A GT 200300193A GT 200300193 A GT200300193 A GT 200300193A GT 200300193 A GT200300193 A GT 200300193A
Authority
GT
Guatemala
Prior art keywords
formulations
indolinone compound
formulation
indolinona
indolinones
Prior art date
Application number
GT200300193A
Other languages
English (en)
Inventor
Paolo Gatti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200300193(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200300193A publication Critical patent/GT200300193A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMULACIONES DE INDOLINONAS, EN LA QUE LA ANTERIOR ES LA FORMULA GENERAL I EN LA QUE R1,R2,R3,R4,R5,R6,R7, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. LA FORMULACION ES ADECUADA PARA ADMINISTRACION PARENTERAL U ORAL, EN DONDE LA FORMULACION COMPRENDE, ADEMAS DEL ACTIVO DE INDOLINONA, UN VEHICULO ACEPTABLE PARA USO FARMACEUTICO.
GT200300193A 2002-09-10 2003-09-10 Formulaciones que comprenden un compuesto de indolinona GT200300193A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42113302P 2002-09-10 2002-09-10

Publications (1)

Publication Number Publication Date
GT200300193A true GT200300193A (es) 2004-04-29

Family

ID=31994326

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300193A GT200300193A (es) 2002-09-10 2003-09-10 Formulaciones que comprenden un compuesto de indolinona

Country Status (31)

Country Link
US (1) US20040229930A1 (es)
EP (1) EP1536783B2 (es)
JP (1) JP2006503032A (es)
KR (1) KR20050059170A (es)
CN (1) CN1688304A (es)
AR (1) AR041193A1 (es)
AT (1) ATE403425T1 (es)
AU (1) AU2003280108B2 (es)
BR (1) BR0314182A (es)
CA (1) CA2498415C (es)
DE (1) DE60322720D1 (es)
DK (1) DK1536783T3 (es)
DO (1) DOP2003000708A (es)
ES (1) ES2309363T5 (es)
GT (1) GT200300193A (es)
HN (1) HN2003000272A (es)
MX (1) MXPA05002690A (es)
MY (1) MY136767A (es)
NL (1) NL1024261C (es)
NO (1) NO20051670L (es)
NZ (1) NZ538636A (es)
PA (1) PA8581801A1 (es)
PE (1) PE20040989A1 (es)
PL (1) PL375978A1 (es)
PT (1) PT1536783E (es)
RU (1) RU2005110663A (es)
SI (1) SI1536783T1 (es)
TW (1) TW200418836A (es)
UY (1) UY27969A1 (es)
WO (1) WO2004024127A2 (es)
ZA (1) ZA200501897B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2348623T3 (es) * 2003-10-02 2010-12-09 PHARMACIA & UPJOHN COMPANY LLC Sales y polimorfos de un compuesto de indolinona sustituidos con pirrol.
MX2008001041A (es) * 2005-09-20 2008-03-19 Pfizer Prod Inc Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa.
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP2253629A1 (en) * 2007-11-21 2010-11-24 Teva Pharmaceutical Industries Ltd. Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2240174A1 (en) * 2008-02-13 2010-10-20 Ratiopharm GmbH Pharmaceutical compositions comprising n-ý2-(diethylamino)ethyl¨-5-ý(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl¨-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2138167A1 (en) * 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
CA2731605A1 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
WO2010039798A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Amorphous compositions of sunitinib base and l-malic acid
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN103301116A (zh) * 2012-03-16 2013-09-18 大鹏药品工业株式会社 口服医药组合物
EP2844282B1 (en) 2012-05-04 2019-06-12 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens
CN104069076A (zh) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 一种无定型的舒尼替尼与pvp的组合物
KR102006527B1 (ko) 2013-11-01 2019-08-02 화이자 인코포레이티드 전립선-연관 항원의 발현을 위한 벡터
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104829596B (zh) * 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
EA202191904A1 (ru) * 2019-01-09 2021-10-04 Селджин Корпорейшн Фармацевтические композиции, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и способы их применения
WO2022006512A1 (en) * 2020-07-02 2022-01-06 The Board Of Regents Of The University Of Texas System Methods of treatment for melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
ES2367007T3 (es) * 1999-11-24 2011-10-27 Sugen, Inc. Derivados de indolinona ionizables y su uso como ligandos de ptk.
DE19956598A1 (de) * 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
NZ520640A (en) * 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors
CA2455050C (en) * 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
TWI259081B (en) † 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds

Also Published As

Publication number Publication date
NL1024261C (nl) 2010-04-06
CA2498415C (en) 2007-05-29
RU2005110663A (ru) 2005-09-10
PT1536783E (pt) 2008-10-10
CN1688304A (zh) 2005-10-26
KR20050059170A (ko) 2005-06-17
NZ538636A (en) 2006-04-28
NL1024261A1 (nl) 2004-03-11
AU2003280108A1 (en) 2004-04-30
PL375978A1 (en) 2005-12-12
MXPA05002690A (es) 2005-05-05
HN2003000272A (es) 2008-07-29
EP1536783A2 (en) 2005-06-08
UY27969A1 (es) 2004-04-30
AR041193A1 (es) 2005-05-04
EP1536783B2 (en) 2011-08-24
NO20051670L (no) 2005-04-04
PA8581801A1 (es) 2005-02-04
DK1536783T3 (da) 2008-10-13
ES2309363T3 (es) 2008-12-16
WO2004024127A3 (en) 2004-06-03
PE20040989A1 (es) 2004-12-28
WO2004024127A2 (en) 2004-03-25
ZA200501897B (en) 2005-09-07
BR0314182A (pt) 2005-08-09
TW200418836A (en) 2004-10-01
AU2003280108B2 (en) 2007-04-05
JP2006503032A (ja) 2006-01-26
US20040229930A1 (en) 2004-11-18
DOP2003000708A (es) 2004-03-31
MY136767A (en) 2008-11-28
CA2498415A1 (en) 2004-03-25
ATE403425T1 (de) 2008-08-15
SI1536783T1 (sl) 2008-12-31
ES2309363T5 (es) 2011-12-07
DE60322720D1 (de) 2008-09-18
EP1536783B1 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
GT200300193A (es) Formulaciones que comprenden un compuesto de indolinona
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
GT200700060A (es) Compuestos de benzimidazolilo
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
ECSP099663A (es) Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y métodos para utilizar la misma
NI200700102A (es) Derivados de indol tetraciclicos como agentes antiviricos
GT200300129A (es) Derivados de heteroarilamida benzo condensada de tienopiridinas utiles como agentes terapeuticos,composiciones farmaceuticas que incluyen a los mismos y metodo para su uso
PA8494101A1 (es) Derivados heterociclicos utiles como agentes anticancerosos
CR8333A (es) Derivados biciclicos [3.1.0 ] como inhibidores del transportador de glicina
AR062448A1 (es) Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
CY1105162T1 (el) Ενωσεις και η χρηση τους ως αναστολεις 5-ητ
CO5590918A2 (es) Formulaciones
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
TW200637817A (en) 5-aminoindole derivatives
ATE450499T1 (de) Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
UY27979A1 (es) Indoles sustituidos en posición 2,4